What’s New in Evaluate
In this page
Evaluate is constantly updating and expanding our data to provide our users with the best and most informative experience possible. Below you will find information and links related to our most recent enhancements
Consensus Forecast Extended to 2024
All consensus sales forecasts have been extended from 2022 to 2024.
This extension allows for:
Reports Extended to 2024
EvaluatePharma has created the first rules-
How Lead Asset Adds Value:
Mechanism of Action
EvaluatePharma has launched new mechanism of action classification across all indications.
The Mechanism of Action (MoA) Classification and accompanying analyses provide a critical lens to monitor and gain insight to the market and competitive landscape, track innovation and identify research and commercial activity around an MoA.
The new product-